Introduction: Asthma affects 30 million people in Western Europe, leading to substantial
INTRODUCTION
Asthma is a common chronic disease of the respiratory system affecting approximately 30 million people in Western Europe [1] and is a serious public health issue. Both direct and indirect per patient costs associated with asthma are high [2, 3] and total asthma care costs are estimated at £18 billion per year in Europe [4] . Resource use due to asthma varies across several European countries but is generally high [2, 4, 5] . For example, in France and Spain, estimated per patient costs for a 3-month period were up to €537.9 and €556.8, respectively [2] . Furthermore, absence from work or education due to asthma is also common [2, 5, 6] . In France and Spain, estimated indirect costs accounted for up to 63% and 59% of total costs, respectively [2] .
Patients with asthma may achieve various levels of control of their asthma, depending on several factors, which may include severity, exposure to triggers, treatments and patient adherence to treatment. The Global Initiative for Asthma (GINA) has developed recommendations to help establish local guidelines that inform and support health professionals' assessment and management of asthma patients. The GINA report defines and categorizes asthma control levels as 'well controlled', 'partly controlled', and 'uncontrolled' based on daytime symptoms, normal activities affected by symptoms, nighttime awakenings, and reliever inhaler use [7] . The recommendations are that management and treatment should be driven by these control levels [7] . However, despite GINA recommendations and existing local guidelines, there are no standard management algorithms or practices for asthma patients across Europe.
The REcognise Asthma and LInk to Symptoms and Experience (REALISE TM ) survey investigated asthma control and evaluated patient perception of control and attitudes to asthma in a large European Union-based population. The data were collected from adult patients with asthma requiring treatment across 11 European countries and included 8000 individuals [8] . In addition, the survey also collected data on patient utilization of healthcare resources and time off work, providing a unique opportunity to assess the resource burden and lost productivity associated with asthma.
Using results from the REALISE TM study, the objective of this research was to understand the burden of asthma by reviewing resource use were excluded from answering the next question of how many times in the past year the respondent had visited the HCP. Answers of ''less than once a year'' were assumed to be zero during the previous 12 months.
Resource use was measured by quantifying how many times a patient reported seeing their main HCP for their asthma or being treated in an A&E department in the previous year. In addition, the number of hospitalizations with an overnight stay relating to asthma during the previous year was reported by each respondent.
Number of days of hospitalization was not reported. Productivity loss was measured in days off work or education. To calculate relative resource use and productivity, odds ratios (ORs) were calculated against the country with the lowest proportion of respondents for hospitalization (as a proxy for lowest resource use). The OR was calculated by dividing the country ratio (respondents using resource versus respondents not using resource) by the reference country ratio (respondents using resource versus respondents not using resource) across all countries.
Productivity and resource use by type of HCP were further analyzed in cross-tabulations.
Analyses were performed using SPSS version 9.0 (SPSS, Inc., Chicago, IL, USA). As there were no a priori hypotheses, and to control for type I family-wise error rate (the probability of at least 1 incorrect rejection of null), effect sizing was determined using the false discovery rate method [9] . The proportion of errors among those tests whose null hypotheses were rejected was set at 5% and P values were calculated to determine statistical significance.
RESULTS

Survey Population and Respondent Characteristics
The analysis included 8000 respondents aged 18-50 years. France, Spain, Italy, Germany, and the UK reported the largest samples (N C 1000). Table 1 shows the respondents' mean age, sex, and smoking status as well as self-reported clinical factors (e.g., controlled GINA status, asthma exacerbation), and ownership and use of preventer inhaler by country.
The mean age range was 32-37 years and between 17% and 26% of respondents were current smokers: patient demographics were broadly similar across countries and statistically significant differences were reported in only a few instances, e.g., respondents in the Netherlands were older than in other countries. The proportion of female respondents was higher in the Netherlands and the UK compared to other countries in the study. The most commonly reported comorbidities were depression and high blood pressure/hypertension, reported by up to 30% of respondents in some countries. Chronic obstructive pulmonary disease, cancer, heart disease, diabetes, and rheumatoid arthritis were reported by less than 10% of respondents in most countries.
On average, 20% of respondents in this study had a controlled GINA status (self-reported), this ranged from 15% in Germany to 28% in Austria. Self-reported asthma exacerbation, indicated by the requirement of at least one course of steroid tablets in the previous 12 months, was highest among respondents in Italy compared with respondents in other countries. In each country in the study, at least one in four respondents possessed a preventer inhaler. Of these respondents, daily use of preventer inhaler was highest in the Netherlands (61%) and Germany (61%) and lowest in Spain (25%). Additionally, between 19% (UK) and 32% (Spain) of respondents owned a combination inhaler (i.e., combination inhaled corticosteroid/longacting beta agonist) and between 7% (UK) and 30% (Belgium) of respondents took oral treatment to help manage their asthma.
HCPs That Respondents Would Consult as the Main HCP for Their Asthma
In all countries, except for Austria, most respondents considered general practitioners (GPs) to be the main HCP they would consult about their asthma (Fig. 1) . The UK was unique among the respondent sample, in that over 25% of respondents considered a nurse to be their main asthma HCP and fewer respondents (4%) would consider seeing a specialist. In contrast, at least 10% of respondents in all other countries considered a specialist as the main HCP they would consult about their asthma; this was highest in Austria (50%) followed by Germany (42%), Spain (37%), and Italy (35%). Respondents who considered a specialist their main asthma HCP (rather than a GP or a nurse) were more likely to be treated at A&E at least once in the previous 12 months (32% specialist, 21% GP, 17% nurse, P B 0.05). Additionally, these respondents also take C1 day off work or education (38% specialist, 30% GP, 22% nurse, P B 0.05; Fig. 2 ). The heterogeneity of HCPs consulted by patients reported in the REALISE TM study could be due to country-specific asthma policies or overall differences in healthcare system structures. In the UK, Sweden, and
Self-Reported Resource Use and Absence From Work or Education Amongst the Respondents in Different Countries
DISCUSSION
Finland for example, asthma nurses are an integral part of the disease management [10] [11] [12] , whereas for example in Germany, asthma nurses do not form part of the management Table 2 Odds ratio and proportions (%) of respondents that reported utilization of healthcare resource or taking at least 1 day off work or education during the previous 12 months by country The proportion of respondents that reported utilization of healthcare resource or taking at least one day off work or education during the previous 12 months was calculated for each country. ORs were calculated from the proportions in relation to the Netherlands (the country with the lowest proportion of respondents for hospitalization-a proxy for lowest resource use) by dividing the country ratio (respondents using resource versus respondents not using resource) by the reference country ratio (respondents using resource versus respondents not using resource across all countries Only respondents who reported a main HCP answered this question plan [13] . If there is no negative impact on patients' asthma control, consulting GPs or nurses more frequently than specialists could indicate overall lower costs to healthcare systems. However, whether such a 'gatekeeper' approach is more appropriate for health systems compared to having the direct access to specialists is unclear and is the subject of much debate in the literature [14] . In addition, in Germany many patients are treated by specialists as German treatment guidelines stipulate that patients should be treated by specialists in cases where: asthma is uncontrolled, long-term treatment with oral corticosteroids is necessary, patient underwent previous emergency treatment, comorbidities exist, suspicion of work-related asthma exists, or treatment with a specific regimen is indicated [13] . In Germany, 42% of respondents considered a specialist their main HCP they would consult about their asthma. This further underpins our findings supporting the validity of our sample frame. Spain [2, 15] . However, the latter study only included asthma patients treated by GPs [2] , while the Italian study was conducted prior to 2000, therefore comparability between studies is limited [15] .
Proportions of respondents reporting hospitalization, A&E visits and absence from work varied across the countries. Similar to previous reports [16] [17] [18] patient-reported asthma control was low, but resource use and work absence appeared to be higher in those countries with low control. This could be due to differences in asthma control levels: in Germany, resource use was high but the proportion of respondents reporting controlled asthma status was low relative to other countries.
In addition, overall resource use was higher for respondents who considered a specialist their main asthma HCP. It is likely that these respondents have more severe asthma than Fig. 2 Proportions of respondents that reported being treated in A&E, hospitalized or taking time off work or education during the previous 12 months, categorized by patient feedback on their main healthcare professional. A&E accident and emergency, GP general practitioner respondents who consult a GP or nurse.
However, due to the study design and analysis plan, we were unable to adjust for any possible contributing factors such as the level of asthma control or severity in this analysis and recommend that future studies incorporate stratified analyses or regression techniques in order to address possible confounding. This would allow the research to identify the drivers for higher resource use which could be the level of asthma control as has been previously suggested [2, 15] . 
